Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 452-458

  Volpato, Stefano ^a   Ferrucci, Luigi ^b   Secchiero, Paola ^a   Corallini, Federica ^a   Zuliani, Giovanni ^a   Fellin, Renato ^a   Guralnik, Jack M ^b   Bandinelli, Stefania ^c   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Azienda Sanitaria di Firenze   (Italy)

Author keywords

Aging; Cardiovascular disease; Epidemiology; Mortality; TRAIL

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECG ABNORMALITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANKLE BRACHIAL INDEX; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; MALE; MIDDLE AGED; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79953055033     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.004     Document Type: Article

References (34)

1. Zauli G., Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine Growth Factor Rev 2006, 17:245-257.
2. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14:337-348.
3. Li J.H., Kirkiles-Smith N.C., McNiff J.M., Pober J.S. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003, 171:1526-1533.
4. O'Brien L.A., Richardson M.A., Mehrbod S.F., et al. Activated protein C decreases tumor necrosis factor related apoptosis-inducing ligand by an EPCR- independent mechanism involving Egr-1/Erk-1/2 activation. Arterioscler Thromb Vasc Biol 2007, 27:2634-2641.
5. Simoncini S., Njock M.S., Robert S., et al. TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. Circ Res 2009, 104:943-951.
6. Zauli G., Pandolfi A., Gonelli A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 2003, 92:732-740.
7. Alladina S.J., Song J.H., Davidge S.T., Hao C., Easton A.S. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 2005, 42:337-347.
8. Secchiero P., Corallini F., di Iasio M.G., Gonelli A., Barbarotto E., Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005, 105:3413-3419.
9. Secchiero P., Candido R., Corallini F., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006, 114:1522-1530.
10. Schoppet M., Sattler A.M., Schaefer J.R., Hofbauer L.C. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006, 184:446-447.
11. Secchiero P., Corallini F., Ceconi C., et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE 2009, 4:e4442.
12. Niessner A., Hohensinner P.J., Rychli K., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
13. Michowitz Y., Goldstein E., Roth A., et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. JAm Coll Cardiol 2005, 45:1018-1024.
14. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
15. Ferrucci L., Bandinelli S., Benvenuti E., et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000, 48:1618-1625.
16. Kaaks R., Riboli E. Validation and calibration of dietary intake measurements in the EPIC project: methodological considerations. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997, 26:S15-S25.
17. The Women's Health and Aging Study: health and social characteristics of older women with disability 1995, National Institute on Aging, Bethesda.
18. Newman A.B., Siscovick D.S., Manolio T.A., et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993, 88:837-845.
19. McDermott M.M., Guralnik J.M., Corsi A., et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 2005, 150:276-281.
20. Fried L.P., Kronmal R.A., Newman A.B., et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. J Am Med Assoc 1998, 279:585-592.
21. Volpato S., Leveille S.G., Corti M.C., Harris T.B., Guralnik J.M. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc 2001, 49:1142-1147.
22. Volpato S., Guralnik J.M., Ferrucci L., et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 2001, 103:947-953.
23. Blaum C.S., Volpato S., Cappola A.R., et al. Diabetes, hyperglycaemia and mortality in disabled older women: the Women's Health and Ageing Study I. Diabet Med 2005, 22:543-550.
24. Liabeuf S., Barreto D.V., Barreto F.C., et al. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 2010, 25:2596-2602.
25. Secchiero P., Zerbinati C., Rimondi E., et al. TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004, 61:1965-1974.
26. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
27. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
28. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818.
29. Secchiero P., Gonelli A., Carnevale E., et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003, 107:2250-2256.
30. Renshaw S.A., Parmar J.S., Singleton V., et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003, 170:1027-1033.
31. Lum J.J., Bren G., McClure R., Badley A.D. Elimination of senescent neutrophils by TNF-related apoptosis-inducing [corrected] ligand. J Immunol 2005, 175:1232-1238.
32. Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J 2009, 73:994-1001.
33. Mori K., Ikari Y., Jono S., et al. Association of serum TRAIL level with coronary artery disease. Thromb Res 2010, 125:322-325.
34. Satoh D., Inami N., Shimazu T., et al. Soluble TRAIL prevents RANTES-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis 2010, 29:471-476.